clinical trial · NCT05361395
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Amgen·phase1·active not recruiting·n = 184
Extensive Stage Small Cell Lung CancerTarlatamabCarboplatinEtoposideAtezolizumabDurvalumab
brief summary
This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.
started
Aug 24, 2022
primary completion
Aug 28, 2028
completion
Aug 28, 2028
last updated
Mar 3, 2026
official title
A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung (DeLLphi-303)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol